Home Research Area Prostate Cancer

Prostate Cancer

In 2022, the global incidence of prostate cancer was estimated to be 1.46 million cases and this is expected to reach approximately 2.4 million by 2040.1

Our prostate cancer portfolio programs target Prostate Specific Membrane Antigen (PSMA) – a protein that is found on the surface of prostate cancer cells and is low or absent on most normal healthy cells. PSMA has become a major breakthrough in finding, and informing treatment and management of prostate cancer. Imaging with targeted radiation (using a PET scan) can identify prostate cancer wherever it is in the body and help guide treatment. 

.

Our prostate cancer portfolio
Our prostate cancer trials

Our prostate cancer portfolio

  • Therapeutics

    • TLX591 (177Lu rosopatamab tetraxetan)

      TLX591 comprises a radioactive isotope, Lutetium-177, attached to an antibody called rosopatamab. TLX591 is Telix’s lead radio antibody-drug conjugate (rADC) directed at PSMA.

      The Phase 3 ProstACT Global study is evaluating how effective and safe TLX591 is in treating prostate cancer, from first reappearance to advanced spread of the cancer.

    • TLX592 (225Ac-RADmAb®)

      Telix’s next generation prostate cancer targeted alpha therapy (TAT) is based on Telix’s proprietary RADmAb® engineered antibody technology.

  • Diagnostics

    • TLX591-CDx (68Ga-PSMA-11)

      Telix’s first generation PSMA-PET imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA),  Australian Therapeutic Goods Administration (TGA),  Health Canada,  United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) and in multiple countries within the European Economic Area (EEA).

      The recent FDA approval of Gozellix® (68Ga-PSMA-11), makes Telix the only company with two approved PSMA imaging agents.

Active Trials

Active trials for Prostate Cancer

View all trials

ProstACT Global
Recruiting
Australia ,  Global ,  New Zealand ,  UK ,  US , 
TLX591 With Best Standard of Care (SoC) for the First or Second Line of Treatment for Metastatic Castration-resistant Prostate Cancer, which Expresses PSMA
Find out more

RHINO
Recruiting
South Africa , 
A theranostic trial exploring the safety and dosimetry of both RHN001-Tx and RHN001-Dx in patients with advanced prostate cancer
Find out more
  1. Elsevier. (2025). Recent patterns and trends in global prostate cancer incidence and mortality. ScienceDirect. https://www.sciencedirect.com/science/article/pii/S0302283824027076